Who owns PLX - PROTALIX BIOTHERAPEUTICS INC - COM based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

PROTALIX BIOTHERAPEUTICS INC - COM (PLX) Institutional Ownership

Q: What is CUSIP 74365A101?

CUSIP 74365A101 is the security identifier used in SEC filing datasets for PLX - PROTALIX BIOTHERAPEUTICS INC - COM.

CUSIP: 74365A101

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2019

Type / Class: Equity / COM
Symbol: PLX on NYSE

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Investment Quick Answers

What is CUSIP 74365A101?
CUSIP 74365A101 identifies PLX - PROTALIX BIOTHERAPEUTICS INC - COM in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Continue Investment Research

Latest 13F filings for new institutional portfolio disclosures.
Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
Latest 10-Q/10-K reports to cross-check issuer fundamentals.
Recent insider transactions for management buying/selling context.
SEC investors directory and top value investors for manager-level discovery.
All institutional ownership pages to compare adjacent CUSIP pages.

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 74365A101:

Q4 2019 (0 holders) Q3 2019 (26 holders) Q2 2019 (26 holders) Q1 2019 (27 holders) Q4 2018 (28 holders) Q3 2018 (35 holders) Q2 2018 (29 holders) Q1 2018 (35 holders) Q4 2017 (34 holders) Q3 2017 (33 holders)

Institutional Holders of PROTALIX BIOTHERAPEUTICS INC - COM (PLX) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2019 Q4	0	$0	-$1,380,205	$0	$0		0
2019 Q3	6,710,352	$1,380,205	-$1,796,168	$3,000	$20,000	$0.20	26
2019 Q2	10,757,108	$5,050,159	+$914,126	$7,000	$46,000	$0.47	26
2019 Q1	8,829,720	$3,853,840	-$702,596	$48,000	$6,000	$0.44	27
2018 Q4	11,223,469	$3,465,421	-$307,773	$34,000	$22,000	$0.31	28
2018 Q3	11,352,650	$8,198,997	+$2,476,917	$82,000	$23,000	$0.73	35
2018 Q2	7,855,174	$3,378,730	-$204,252	$8,000	$0	$0.43	29
2018 Q1	8,278,407	$4,463,738	+$573,815	$27,000	$7,000	$0.54	35
2017 Q4	6,992,647	$4,631,653	-$2,731,024		$0	$0.66	34
2017 Q3	11,001,885	$6,384,450	+$1,313,538	$0	$149,000	$0.58	33
2017 Q2	9,074,781	$7,595,095	-$752,497	$173,000	$137,000	$0.84	34
2017 Q1	8,424,970	$11,449,400	-$5,168,348	$341,000	$193,000	$1.36	25
2016 Q4	19,598,975	$8,721,000	-$3,440,801			$0.44	28
2016 Q3	22,230,499	$12,463,000	-$1,268,270			$0.57	23
2016 Q2	24,210,252	$15,495,000	-$700,302	$9,000		$0.64	22
2016 Q1	25,262,392	$21,231,000	-$1,313,714	$0	$0	$0.84	25
2015 Q4	26,618,439	$27,133,000	-$2,963,264	$52,000	$40,000	$1.02	27
2015 Q3	27,846,747	$32,856,884	-$1,556,593	$26,000	$19,000	$1.18	30
2015 Q2	29,083,626	$56,709,997	+$1,821,247	$47,000	$59,000	$1.95	32
2015 Q1	28,846,836	$51,533,750	-$6,098,203	$27,000		$1.78	35
2014 Q4	32,156,656	$59,321,663	-$183,839	$112,000	$0	$1.84	39
2014 Q3	31,629,191	$76,543,054	-$12,455,828	$321,000	$80,000	$2.42	40
2014 Q2	32,982,807	$120,388,109	-$7,559,899	$1,871,000	$350,000	$3.65	42
2014 Q1	35,010,158	$160,247,214	-$3,537,793	$3,012,000	$143,250	$4.58	41